Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 60.0-90.0,  Osteoporosis, Postmenopausal Subject is willing and able to provide written informed consent Of Chinese origin defined as being born in China, having four ethnic Chinese grandparents Ambulatory woman between the age of 60 and 90 years, inclusive The subject has a BMD absolute value consistent with a T-score<-2.5 and >-4.0 at either the lumbar spine or total hip All subjects must have at least one of following additional the risk factors: history of fracture parental history of hip fracture increased bone turnover rate at screening (s-CTX >1.0 SD above the mean in healthy premenopausal women) low body weight (BMI≤19kg/m2) elderly (age≥70y) current smoker Postmenopausal defined as >5 years postmenopausal, which can be >5 years of spontaneous amenorrhea or >5 years post surgical bilateral oophorectomy. Use follicle stimulating hormone (FSH) levels >40 mIU/mL to confirm surgical postmenopausal status, where bilateral oophorectomy status is uncertain  Bone/metabolic disease: Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings. Paget's disease Cushing's disease Hyperprolactinemia Current hyperparathyroidism or hypoparathyroidism by medical record Thyroid condition: Hyperthyroidism or hypothyroidism. Only subjects with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following If TSH level is below normal range, subject is not eligible for the study. If TSH level is elevated (>5.5 μIU/mL and ≤10.0 μIU/mL), serum T4 should be measured. If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study. If TSH level is > 10.0 μIU/mL, subject is not eligible Rheumatoid arthritis Malignancy: Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5years Malabsorption syndrome: malabsorption syndrome or any gastrointestinal disorders associated with malabsorption, for example Crohn's Disease and chronic pancreatitis Renal disease severe renal impairment Liver disease: Cirrhosis of the liver Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Chronic stable hepatitis B and C are acceptable if the subject otherwise meets study entry (e.g., presence of hepatitis B surface antigen or positive Hepatitis C test result within 3 months of Screening) Drug or alcohol abuse: Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study